24/7 Market News Snapshot 08 September, 2025 – Talphera, Inc. Common Stock (NASDAQ:TLPH)
DENVER, Colo., 08 September, 2025 (www.247marketnews.com) – (NASDAQ:TLPH) are discussed in this article.
Talphera, Inc. has experienced a remarkable stock surge, opening at $0.58 and climbing to $0.753, reflecting an impressive increase of over 37%. This spike follows a previous session close of $0.549, indicating strong investor interest and robust trading momentum, with a significant volume of approximately 6.55 million shares exchanged. Market analysts believe that the current trend showcases an opportunity for further growth in the near term, driven by bullish sentiment surrounding the company.
In a significant strategic move, CorMedix Inc. has announced a $5 million minority equity investment in Talphera, acquiring 9,090,909 shares at $0.55 each. This investment corresponds with Talphera’s recent private placement designed to support the Phase 3 registrational study of its lead product, Niyad™, a cutting-edge formulation of nafamostat aimed at serving as an anticoagulant in extracorporeal circuits. Notably, Niyad has garnered Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
The Phase 3 trial, named NEPHRO CRRT, will enroll 70 adult patients who cannot take heparin or are at increased risk of bleeding, addressing the substantial unmet needs within the acute kidney injury patient demographic. CorMedix’s investment not only financially supports Talphera but also establishes a compelling strategic partnership, securing for CorMedix exclusive rights for a potential acquisition and a board nomination.
Joseph Todisco, CEO of CorMedix, expressed optimism about the partnership, emphasizing Niyad’s potential to improve current continuous renal replacement therapy standards. Conversely, Talphera’s CEO, Vince Angotti, acknowledged the support from CorMedix as validation for Niyad’s potential impact on patient care, with anticipated FDA approval in 2026 positioning it to become the first approved regional anticoagulant for continuous renal replacement therapy, aimed at enhancing patient outcomes in hospital settings.